SER
Serina Therapeutics, Inc.
Key Financials
Gross Profit
$102000
↑ 385.7%
Net Income
$-19182000
↓ 72.2%
Operating Income
$-24022000
↓ 40.9%
Total Assets
$7.0M
↑ 3.4%
Shareholders' Equity
$-37000.00
↓ 105.8%
Total Liabilities
$7.0M
↑ 12.4%
EPS (Diluted)
$-1.91
↓ 26.5%
Cash & Equivalents
$3.1M
↓ 16.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/9/2026 | View on SEC |
| 8-K | 9/9/2026 | View on SEC |
| EFFECT | 8/31/2026 | View on SEC |
| 8-K | 8/27/2026 | View on SEC |
| S-1 | 8/24/2026 | View on SEC |
| S-8 | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 4 | 7/23/2026 | View on SEC |
| 3 | 7/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SER |
| Company Name | Serina Therapeutics, Inc. |
| CIK | 1708599 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | AL |
| Phone | (256) 327-9630 |